SCHEMBL354931

SCHEMBL354931

CNC(C)C(OO)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 2/20 0.57
CHRM2 P08172 1/20 0.57
ADRA1A P35348 1/20 0.57
RGS12 O14924 1/20 0.57
GLA P06280 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
PKM P14618 1/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
ALOX12 P18054 1/20 0.57
NFKB1 P19838 1/20 0.57
HTR2A P28223 1/20 0.57
CYP2C19 P33261 1/20 0.57
THPO P40225 1/20 0.57
GNAI1 P63096 1/20 0.57
HSD17B10 Q99714 1/20 0.57
KMT2A Q03164 3/20 0.55
MEN1 O00255 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186191 0.82 CYP3A4 (0.53) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL14224817 0.82 CYP3A4 (0.53) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL14541701 0.82 CYP3A4 (0.53) ADRA2CCHRM2ADRA1ARGS12GLA
Hydrochloric Acid SCHEMBL68364 0.80 KMT2A (0.55) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL14071918 0.80 HTR2A (0.52) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL9410650 0.80 HTR2A (0.52) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL7051224 0.80 ADRA2C (0.52) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL491203 0.79 ADRA2C (0.41) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL16863765 0.78 CYP2D6 (0.50) ADRA2CCHRM2ADRA1ARGS12GLA
SCHEMBL316701 0.78 CYP2D6 (0.50) ADRA2CCHRM2ADRA1ARGS12GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101137326-B Use of adrenergic imaging agents and adrenergic interfering agents and related kits MEDI PHYSICS INC 2010-10-20 CN claimed
CN-101631566-A Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same KEMPHARM INC 2010-01-20 CN claimed
EP-2109465-A2 POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME Kempharm, Inc. (US) 2009-10-21 EP claimed
US-20080228069-A1 Novel Differential Imaging Method MEDIPHYSICS, INC. (US) 2008-09-18 US claimed
WO-2008098151-A2 POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME KEMPHARM, INC. (US) 2008-08-14 WO claimed
CN-101137326-A Novel differential imaging method MEDI PHYSICS INC (US) 2008-03-05 CN claimed
EP-1691777-A2 NOVEL DIFFERENTIAL IMAGING METHOD Medi-Physics, Inc. (US) 2006-08-23 EP claimed
WO-2005053615-A9 NOVEL DIFFERENTIAL IMAGING METHOD MEDI PHYSICS INC (US) 2005-09-01 WO claimed
WO-2005053615-A2 NOVEL DIFFERENTIAL IMAGING METHOD MEDI-PHYSICS, INC. (US) 2005-06-16 WO claimed
EP-0480934-B1 A SLIMMING PHARMACEUTICAL COMPOSITION NYCOMED DAK AS (DK) 1994-06-29 EP claimed
EP-0480934-A1 A SLIMMING PHARMACEUTICAL COMPOSITION. DAK LAB AS (DK) 1992-04-22 EP claimed
WO-1991000730-A1 A SLIMMING PHARMACEUTICAL COMPOSITION DAK-LABORATORIET A/S (DK) 1991-01-24 WO claimed
US-12583888-B2 Bi-specific extracellular matrix binding peptides and methods of use thereof UNIVERSITY OF TARTU (EE) 2026-03-24 US disclosed
US-12564637-B2 Nucleic acid mazzocchio and methods of making and use thereof THE UNIVERSITY OF HONG KONG (CN) 2026-03-03 US disclosed
US-20260048133-A1 METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) 2026-02-19 US disclosed
EP-3953475-B1 NUCLEIC ACID MAZZOCCHIO AND METHODS OF MAKING AND USE THEREOF UNIV HONG KONG (HK) 2026-01-21 EP disclosed
US-5422352-A Slimming pharmaceutical composition NYCOMED DAK A/S (DK) 1995-06-06 US disclosed
EP-0480934-B1 A SLIMMING PHARMACEUTICAL COMPOSITION NYCOMED DAK AS (DK) 1994-06-29 EP disclosed
EP-0480934-A1 A SLIMMING PHARMACEUTICAL COMPOSITION. DAK LAB AS (DK) 1992-04-22 EP disclosed
WO-1991000730-A1 A SLIMMING PHARMACEUTICAL COMPOSITION DAK-LABORATORIET A/S (DK) 1991-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564637-B2 Nucleic acid mazzocchio and methods of making and use thereof POLRMT, POLM, SSU72 ADRA2C 4606/4885CHRM2 4880/4885ADRA1A 3758/4885
US-20260048133-A1 METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS CMKLR2, CRKL, CMKLR1 ADRA2C 3011/4885CHRM2 3062/4885ADRA1A 4155/4885
US-12583888-B2 Bi-specific extracellular matrix binding peptides and methods of use thereof FN1, EDNRB, TNFSF11 ADRA2C 3859/4885CHRM2 3725/4885ADRA1A 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.